Egberts Jan-Hendrik, Schniewind Bodo, Schafmayer Clemens, Kruse Marie-Luise, Sipos Bence, Fändrich Fred, Kalthoff Holger, Tepel Jürgen
Department of General Surgery and Thoracic Surgery, Schleswig-Holstein University Hospitals, Campus Kiel, Arnold-Heller-Strasse 7, 24105, Kiel, Germany.
Clin Exp Metastasis. 2007;24(3):141-8. doi: 10.1007/s10585-007-9058-x. Epub 2007 Apr 4.
Gallbladder cancer is characterized by high morbidity and mortality. An appropriate human xenograft animal model could serve as a research tool to investigate new therapeutic strategies.
To date, the few reports describing a xenograft animal model showed significant limitations. We improved a murine orthotopic human xenotransplantation model by implanting human gallbladder carcinoma cells directly into the lumen of the gallbladder.
Mz-ChA-1 cells were orthotopically injected into the gallbladder of Severe Combined Immune Deficiency (SCID) beige mice inducing the growth of solid tumors. The natural course of the disease, tumor growth, and metastases were analyzed. The cytotoxic drug gemcitabine was tested in vitro and in vitro.
All animals revealed solid tumors in the inoculated area with liver infiltration. The median tumor volume in the untreated group was significantly higher than in the gemcitabine-treated group. Immunohistochemical staining revealed expression of human cytokeratin 7 and cytokeratin 8. To analyze tumor cell proliferation, the tumors were stained for the antigen Ki-67, and labeling indices were calculated for both groups. Animals receiving gemcitabine treatment showed significantly lower mean labeling indices. In vitro investigation revealed a significant reduction of DNA synthesis. DNA fragmentation, as a measure of apoptosis, was elevated by roughly 20% within 24 h of treatment. With this, we successfully established an orthotopic xenotransplant animal model and investigated the in vitro and in vivo effects of gemcitabine in human xenografted Mz-ChA-1 gallbladder adenocarcinoma.
This model resembles the clinical situation as closely as possible and offers a relevant option for the preclinical testing of new therapeutic strategies.
胆囊癌具有高发病率和高死亡率的特点。合适的人源异种移植动物模型可作为研究新治疗策略的工具。
迄今为止,少数描述异种移植动物模型的报告显示出明显的局限性。我们通过将人胆囊癌细胞直接植入胆囊腔内,改进了一种小鼠原位人异种移植模型。
将Mz-ChA-1细胞原位注射到严重联合免疫缺陷(SCID)米色小鼠的胆囊中,诱导实体瘤生长。分析疾病的自然进程、肿瘤生长和转移情况。对细胞毒性药物吉西他滨进行了体外和体内测试。
所有动物在接种部位均出现实体瘤并伴有肝脏浸润。未治疗组的肿瘤体积中位数显著高于吉西他滨治疗组。免疫组织化学染色显示人细胞角蛋白7和细胞角蛋白8的表达。为分析肿瘤细胞增殖情况,对肿瘤进行Ki-67抗原染色,并计算两组的标记指数。接受吉西他滨治疗的动物平均标记指数显著较低。体外研究显示DNA合成显著减少。作为凋亡指标的DNA片段化在治疗24小时内升高了约20%。据此,我们成功建立了一种原位异种移植动物模型,并研究了吉西他滨在人异种移植的Mz-ChA-1胆囊腺癌中的体外和体内作用。
该模型尽可能贴近临床情况,为新治疗策略的临床前测试提供了一个相关选择。